<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04329130</url>
  </required_header>
  <id_info>
    <org_study_id>B2020-013</org_study_id>
    <nct_id>NCT04329130</nct_id>
  </id_info>
  <brief_title>Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma</brief_title>
  <official_title>Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma: an Open Label, Single Arm, Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this open label,single arm,phase Ⅱ clinical trail is to determine the safety
      and efficacy of Chidamide combination with lenalidomide for relapsed or refractory peripheral
      T-cell lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Histone deacetylase(HDAC) inhibitor has been used in relapsed or refractory peripheral T-cell
      lymphoma.There are no international studies of Chidamide combination with lenalidomide for
      relapsed or refractory peripheral T-cell lymphoma. Therefore, this study intends to select
      the oral HDAC inhibitor Chidamide combined with lenalidomide for relapsed or refractory
      peripheral T-cell lymphoma, and explore its efficacy and safety.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 27, 2020</start_date>
  <completion_date type="Anticipated">March 26, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 26, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>4-years</time_frame>
    <description>Overall Response Rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>4-years</time_frame>
    <description>Progression Free Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR</measure>
    <time_frame>4-years</time_frame>
    <description>Duration of Overall Response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>4-years</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Relapsed or Refractory Peripheral T-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Chidamide combined Lenalidomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chidamide, 20 mg, twice per week; lenalidomide, 25 mg, d1-21, and rest for 7 days.
one treatment cycle per 28 days.For patients with limited lesions and good drug response, local radiotherapy may be assessed by the investigator.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chidamide, Lenalidomide</intervention_name>
    <description>All patients enrolled in the study will accept Chidamide combination with lenalidomide regimen.</description>
    <arm_group_label>Chidamide combined Lenalidomide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  peripheral T cell lymphoma (PTCL);

          -  no remission or relapse after at least one previous systemic treatment；

          -  at least one assessable lesion；

          -  18-75 years;

          -  ECOG PS 0-2;

          -  proper functioning of the major organs;

          -  expected survival time ≥3 months.

        Exclusion Criteria:

          -  previous received treatment of HDAC inhibitor or lenalidomide;

          -  central nervous system (CNS) involvement;

          -  serious heart problems;

          -  known allergies to experimental drug ingredients;

          -  diagnosed with or receiving treatment for a malignancy other than lymphoma;

          -  uncontrolled active infection, with the exception of tumor-related b-symptom fever;

          -  unable or unwilling to receive antithrombotic therapy;

          -  history of deep vein thrombosis (DVT) or pulmonary embolism (PE) in the past 12
             months;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qingqing Cai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qingqing Cai, MD</last_name>
    <phone>0086-20-87342823</phone>
    <email>caiqq@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Guangdong General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenyu Li, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 28, 2020</study_first_submitted>
  <study_first_submitted_qc>March 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2020</study_first_posted>
  <last_update_submitted>April 22, 2020</last_update_submitted>
  <last_update_submitted_qc>April 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Qingqing Cai</investigator_full_name>
    <investigator_title>Chief physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

